Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cloud Pharmaceuticals has completed 17 new computational drug discovery projects using its Quantum Molecular Design process to design molecules targeting a range of indications.
Subscribe to our email newsletter
The completion has resulted in various development programs including those that target AMPK, eiF4E, Metnase, MTH1, PERK, and other indications.
The company is working with partners to develop a range of fractionally-owned drugs and a focused pipeline of wholly-owned drugs.
A partnership between Cloud Pharmaceuticals and THERAMetrics is engaged in the design and development of therapeutics for orphan central nervous system diseases and other indications.
The collaboration is initially focusing on orphan diseases like Huntington’s disease, amyotrophic lateral sclerosis, progressive supranuclear palsy, and frontotemporal dementia.
The University of Florida Department of Medicine has also partnered with Cloud Pharmaceuticals to share intellectual property and provide funding for 12 research projects.
The alliance has designed several novel inhibitors of the MTH1 protein, an enzyme which is essential for cancer cell proliferation.
Cloud Pharmaceuticals CEO Ed Addison said: "Over the past year, much of our work has focused on several areas of therapeutic focus including cancer, metabolic and cardiovascular disease, and central nervous system disorders.
"Our strategy is to work with organizations to jointly design new drugs and then partner with later-stage developers. The results we’ve achieved demonstrate that our process is working and resulting in low-cost, high-value molecules."
The company collaborates with partners at every phase of drug development including early stage, preclinical, IND, and the clinic.